Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23756677
DOI
10.1038/ijo.2013.108
PII: ijo2013108
Knihovny.cz E-resources
- MeSH
- Adipokines metabolism MeSH
- Adipose Tissue, White metabolism pathology MeSH
- Diet, High-Fat MeSH
- Dietary Fats MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Energy Metabolism MeSH
- Immunohistochemistry MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Docosahexaenoic Acids pharmacology MeSH
- Fatty Acids, Omega-3 pharmacology MeSH
- Mice, Inbred C57BL MeSH
- Mice, Obese MeSH
- Mice MeSH
- Obesity immunology pathology MeSH
- Rosiglitazone MeSH
- Thiazolidinediones pharmacology MeSH
- Adipocytes metabolism MeSH
- Inflammation pathology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adipokines MeSH
- Dietary Fats MeSH
- Docosahexaenoic Acids MeSH
- Fatty Acids, Omega-3 MeSH
- Rosiglitazone MeSH
- Thiazolidinediones MeSH
OBJECTIVE: Resolution of low-grade inflammation of white adipose tissue (WAT) is one of the keys for amelioration of obesity-associated metabolic dysfunctions. We focused on the identification of adipokines, which could be involved at the early stages of resolution of WAT inflammation. METHODS AND PROCEDURE: Male C57BL/6J mice with obesity induced in response to a 22-week feeding corn oil-based high-fat (cHF) diet were divided into four groups and were fed with, for 2 weeks, control cHF diet or cHF-based diets supplemented with: (i) concentrate of n-3 long-chain polyunsaturated fatty acids, mainly eicosapentaenoic and docosahexaenoic acids (cHF+F); (ii) thiazolidinedione drug rosiglitazone (cHF+TZD); and (iii) both compounds (cHF+F+TZD). RESULTS: The short-term combined intervention exerted additive effect in the amelioration of WAT inflammation in obese mice, namely in the epididymal fat, even in the absence of any changes in either adipocyte volume or fat mass. The combined intervention elicited hypolipidaemic effect and induced adiponectin, whereas the responses to single interventions (cHF+F, cHF+TZD) were less pronounced. In addition, analysis in WAT lysates using protein arrays revealed that the levels of a small set of adipose tissue-related proteins, namely macrophage inflammatory protein 1γ, endoglin, vascular cell adhesion molecule 1 and interleukin 1 receptor antagonist, changed in response to the anti-inflammatory interventions and were strongly reduced in the cHF+F+TZD mice. These results were verified using both the analysis of gene expression and enzyme-linked immunosorbent analysis in WAT lysates. In contrast with adiponectin, which showed changing plasma levels in response to dietary interventions, the levels of the above proteins were affected only in WAT. CONCLUSIONS: We identified several adipose tissue-related proteins, which are locally involved in resolution of low-grade inflammation and remodelling of WAT.
See more in PubMed
Int J Obes (Lond). 2012 Feb;36(2):262-72 PubMed
FEBS Lett. 2003 Jul 31;548(1-3):125-30 PubMed
Lipids. 2004 Dec;39(12):1177-85 PubMed
Diabetes. 1999 Jan;48(1):134-40 PubMed
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22504-9 PubMed
Gene. 2004 Sep 29;340(1):141-50 PubMed
J Clin Endocrinol Metab. 2002 Mar;87(3):1184-8 PubMed
Diabetologia. 2005 Nov;48(11):2365-75 PubMed
Science. 1987 Aug 21;237(4817):885-8 PubMed
PLoS One. 2012;7(6):e38834 PubMed
Diabetologia. 2011 Oct;54(10):2626-38 PubMed
Diabetes. 2010 Oct;59(10):2495-504 PubMed
Diabetes. 2006 Apr;55(4):924-8 PubMed
PLoS One. 2012;7(8):e43764 PubMed
Nat Med. 2001 Dec;7(12):1291-7 PubMed
Diabetes. 2007 Apr;56(4):1034-41 PubMed
J Clin Endocrinol Metab. 2009 Sep;94(9):3171-82 PubMed
Diabetologia. 2004 Dec;47(12):2215-25 PubMed
Int J Obes (Lond). 2007 Jun;31(6):1004-13 PubMed
Am J Physiol. 1993 Jun;264(6 Pt 2):R1111-8 PubMed
J Lipid Res. 1997 Oct;38(10):1963-72 PubMed
Clin Sci (Lond). 2009 Jan;116(1):1-16 PubMed
Diabetes. 2005 Jul;54(7):2003-11 PubMed
Diabetologia. 2007 Mar;50(3):654-65 PubMed
Nat Rev Endocrinol. 2012 Dec;8(12):709-16 PubMed
Diabetes. 2003 May;52(5):1104-10 PubMed
Ann Med. 2009;41(6):471-8 PubMed
Mol Cell Endocrinol. 2010 Jan 15;314(1):1-16 PubMed
Diabetologia. 2009 May;52(5):941-51 PubMed
PLoS One. 2011;6(11):e27126 PubMed
Am J Clin Nutr. 2012 Nov;96(5):1137-49 PubMed
Physiol Res. 2010;59(1):79-88 PubMed
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10626-31 PubMed
FEBS Lett. 1999 Feb 12;444(2-3):206-10 PubMed
Diabetes. 2005 Dec;54(12):3358-70 PubMed
PPAR Res. 2007;2007:81219 PubMed
Nat Chem Biol. 2010 Jun;6(6):433-41 PubMed
J Hum Nutr Diet. 2004 Oct;17(5):449-59 PubMed
Trends Immunol. 2011 Jul;32(7):307-14 PubMed
Diabetologia. 2006 Feb;49(2):394-7 PubMed
Int J Obes (Lond). 2008 May;32(5):772-9 PubMed
Biochem Biophys Res Commun. 2004 Oct 15;323(2):630-5 PubMed
Am J Physiol Endocrinol Metab. 2010 Sep;299(3):E437-45 PubMed
Diabetes. 2003 Jul;52(7):1655-63 PubMed
Endocrinology. 2012 Apr;153(4):1706-16 PubMed
Diabetes. 2009 Nov;58(11):2574-82 PubMed
Nat Rev Immunol. 2006 Oct;6(10):772-83 PubMed
J Clin Invest. 2011 Jun;121(6):2111-7 PubMed
Front Immunol. 2012 Oct 22;3:298 PubMed
